November 2008 Oncology News International

News
Article

  • Cover Story
  • Elaine Jaffe: At the forefront of clinical lymphoma biology
  • Clinical trials struggle to recruit, retain patients
  • New task force guideline returns PSA screening to center stage

DEPARTMENTS

International News

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Related Content
No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

Roman Fabbricatore
November 2nd 2025
Article

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Ariana Pelosci
November 2nd 2025
Article

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Tim Cortese
November 1st 2025
Article

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

AI may transform oncology with Scout, an innovative assistant enhancing clinical insights and treatment strategies for TP53-mutant MCL and multiple myeloma.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

Gina Mauro
November 1st 2025
Article